FDA Advisors Reject AstraZeneca's Breast Cancer Drug, Stock Drops
An FDA advisory committee voted 6-3 against camizestrant, AstraZeneca's experimental breast cancer drug, citing concerns over trial design and uncertainty about long-term patient benefits. The decision sent AstraZeneca's stock sinking. The vote is non-binding but influential on the FDA's final approval decision.
Key facts
- FDA advisory committee voted 6-3 against camizestrant
- Camizestrant is AstraZeneca's breast cancer drug
- Concerns cited: trial design and long-term patient benefit
- AstraZeneca stock sank after the vote
- The vote is non-binding but influential
Entities
Institutions
- AstraZeneca
- FDA
Sources
- Quartz —